Cosmina Georgiana Ponor

Dr. Cosmina Georgiana Ponor

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2026 in Life
Verified
Journal Article
Open access
PDF file
CPCosmina Georgiana Ponor
Cosmina Georgiana Ponor
MCMaria-Ruxandra Cepoi
Maria-Ruxandra Cepoi
MSMarilena Renata Spiridon
Marilena Renata Spiridon
ITIonut Tudorancea
Ionut Tudorancea
ABAmelian Bobu
Amelian Bobu
Irina Iuliana COSTACHE-ENACHEIrina Iuliana COSTACHE-ENACHE
Irina Iuliana COSTACHE-ENACHE
Background: Systemic venous congestion is a key driver of organ dysfunction in heart failure (HF), yet accurate non-invasive quantification remains challenging. Recognizing residual congestion is critical, since it predicts HF readmissions and mortality. Traditional assessments (physical exam, jugular venous pressure, inferior vena cava [IVC] size) are imprecise. The Venous Excess Ultrasound Score (VExUS) is a semi-quantitative point-of-care ultrasound (POCUS) protocol that integrates IVC diameter with Doppler flow patterns in the hepatic, portal and intrarenal veins to grade systemic venous overload. Methods: We conducted a narrative review of literature (2018–2025) regarding the usefulness of VExUS in HF, covering congestion pathophysiology, clinical evidence (hemodynamic correlations, organ dysfunction, outcomes), potential applications, integration with lung ultrasound, echocardiography and biomarkers, limitations of its assessment and future directions. Results and Discussions: In HF, elevated right atrial pressure causes venous congestion. VExUS integrates IVC diameter with Doppler waveforms of hepatic, portal, and intrarenal veins to grade congestion. Emerging evidence shows higher VExUS grades correlate with elevated filling pressures, renal dysfunction, and worse outcomes. Its use may guide diuretic therapy, aid discharge planning, and monitor outpatient congestion, especially when combined with lung ultrasound and biomarkers. However, VExUS has limitations: it is technical and operator-dependent. Importantly, large trials validating VExUS-guided management are lacking. Future directions include AI-driven automation of Doppler analysis and integration with multimodal congestion monitoring to provide a comprehensive congestion assessment. Conclusions: VExUS is a promising noninvasive tool for quantifying congestion in HF. Higher grades are associated with organ dysfunction and poor prognosis. Incorporating this technique into HF care may improve congestion-guided therapy, but large-scale validation is required before routine use.

17 April 2025 in Life
Verified
Journal Article
Open access
PDF file
SCSandu Cucuta
Sandu Cucuta
Minerva Codruta BadescuMinerva Codruta Badescu
Minerva Codruta Badescu
ŞDŞtefania Teodora Duca
Ştefania Teodora Duca
ACAdriana Chetran
Adriana Chetran
MCMaria-Ruxandra Cepoi
Maria-Ruxandra Cepoi
Irina Iuliana COSTACHE-ENACHEIrina Iuliana COSTACHE-ENACHE
Irina Iuliana COSTACHE-ENACHE
Pulmonary thromboembolism (PE) is a life-threatening condition that often leads to right ventricular (RV) dysfunction, a key determinant of prognosis and clinical management. Biomarkers play a crucial role in the early detection and risk stratification of RV dysfunction in PE, complementing imaging and hemodynamic assessments. Cardiac troponins, B-type natriuretic peptides, and novel biomarkers, such as heart-type fatty acid-binding protein (H-FABP) and growth differentiation factor-15 (GDF-15), provide valuable insights into myocardial injury, overload, and stress. This article explores the clinical possible significance of these biomarkers, their predictive value, and their potential to guide therapeutic strategies in patients with PE. Understanding the role of biomarkers in RV dysfunction assessment may improve patient outcomes focusing on early intervention and personalized treatment approaches.

21 March 2026 in Life
Verified
Journal Article
Open access
PDF file
ABAmelian Bobu
Amelian Bobu
ŞDŞtefania Teodora Duca
Ştefania Teodora Duca
ACAndrei Ionut Cucu
Andrei Ionut Cucu
ADAvieritei Diana-Alina
Avieritei Diana-Alina
CPCosmina Georgiana Ponor
Cosmina Georgiana Ponor
Irina Iuliana COSTACHE-ENACHEIrina Iuliana COSTACHE-ENACHE
Irina Iuliana COSTACHE-ENACHE
Type 2 diabetes mellitus is associated with major cardiovascular complications, including cardiac autonomic neuropathy, which contributes to sympathetic–parasympathetic imbalance and increases susceptibility to arrhythmias and sudden cardiac death. Heart rate variability, assessed through R–R intervals on electrocardiography and 24 h Holter monitoring, represents a sensitive, non-invasive marker of autonomic dysfunction and arrhythmogenic risk. In patients with type 2 diabetes mellitus, chronic hyperglycaemia, oxidative stress, and metabolic inflammation lead to early impairment of the autonomic nervous system, manifested by consistent reductions in SDNN, RMSSD, pNN50, total power, and the high-frequency component, indicating diminished parasympathetic tone and sympathetic predominance. Nonlinear HRV indices demonstrate a loss of complexity and fractal organisation, providing additional prognostic value beyond conventional time- and frequency-domain analyses. Reduced HRV correlates with the severity of cardiac autonomic neuropathy, duration of diabetes, and poor glycaemic control, identifying patients with increased arrhythmogenic vulnerability. HRV analysis enables prediction of arrhythmic risk, facilitating the identification of high-risk individuals and guiding personalised interventions. The integration of HRV assessment into routine clinical practice may improve the early detection of subclinical autonomic neuropathy and optimise cardiovascular risk stratification and management in patients with type 2 diabetes mellitus.

1 December 2024 in Romanian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
CPCosmina Georgiana Ponor
Cosmina Georgiana Ponor
LCLoredana Arabela Clapa
Loredana Arabela Clapa
RMRadu Ștefan Miftode
Radu Ștefan Miftode
ȘPȘtefan Eduard Popescu
Ștefan Eduard Popescu
CLCristian Dumitru LupașCu
Cristian Dumitru LupașCu
VBVlad BrașOveanu
Vlad BrașOveanu
Introduction: Takotsubo syndrome is an acute reversible heart failure syndrome, and its secondary form occurs in patients already hospitalized for another medical, surgical, obstetric, or psychiatric condition. Takotsubo syndrome is also a complication that occurs in liver transplant recipients. There is little data regarding the management and long-term treatment of these patients; major recommendations are based on expert opinion. Case Presentation: We present a case of a 46-year-old female patient, with no significant past medical history, admitted for hepatectomy, being a living hepatic transplant donor for her sister. In the early postoperative period, she developed worsening dyspnea, alongside ECG changes, abnormal cardiac biomarkers, and a significant decrease of the left ventricle systolic function, with a typical “apical ballooning” aspect of the left ventricle determined by the wall motion abnormalities that extend beyond the territory of a single coronary artery. All the clinical and imagistic aspects are highly suggestive of Takotsubo syndrome. She further developed a low cardiac output state and cardiogenic shock, with a recovery of her clinical state days later, being under supportive care, with a later improvement of her symptoms and of the left ventricle systolic function on repeated transthoracic echocardiography. Conclusions: Takotsubo syndrome may be a complication occurring in liver transplant recipients, with a rising number of cases published. Secondary Takotsubo syndrome occurring in a living liver donor is in itself a peculiarity due to the fact that such cases are not currently reported in literature. We report this case to raise awareness regarding this possible outcome in living donors for solid organ transplantation.